Natural immunization against malaria: Causal prophylaxis with antibiotics

Science Translational Medicine

Volumn 2, Issue 40, 2010, Pages

  Friesen, Johannes ^a,b   Silvie, Olivier ^a,b   Putrianti, Elyzana Dewi ^a,b   Hafalla, Julius C R ^c   Matuschewski, Kai ^a,b   Borrmann, Steffen ^a,d  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b MAX PLANCK INSTITUTE FOR INFECTION BIOLOGY   (Germany)

^c LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^d KEMRI WELLCOME TRUST RESEARCH PROGRAMME   (Kenya)

Author keywords

[No Author keywords available]

Indexed keywords

AZITHROMYCIN; CLINDAMYCIN; ANTIINFECTIVE AGENT; GAMMA INTERFERON;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBIOTIC THERAPY; APICOPLAST; ARTICLE; CONTROLLED STUDY; FEMALE; IMMUNITY; IMMUNIZATION; IN VITRO STUDY; MEROZOITE; NONHUMAN; PARASITE TRANSMISSION; PLASMODIUM (LIFE CYCLE STAGE); PLASMODIUM BERGHEI; PLASMODIUM BERGHEI INFECTION; PRIORITY JOURNAL; PROPHYLAXIS; REINFECTION; SPOROZOITE; ANIMAL; ANTIBIOTIC PROPHYLAXIS; BLOOD; C57BL MOUSE; CD8+ T LYMPHOCYTE; CELL CULTURE; CYTOLOGY; DRUG EFFECT; ERYTHROCYTE; GROWTH, DEVELOPMENT AND AGING; IMMUNOLOGY; LIFE CYCLE STAGE; LIVER; MALARIA; MOUSE; PARASITOLOGY;

ANIMALS; ANTI-BACTERIAL AGENTS; ANTIBIOTIC PROPHYLAXIS; AZITHROMYCIN; CD8-POSITIVE T-LYMPHOCYTES; CELLS, CULTURED; CLINDAMYCIN; ERYTHROCYTES; FEMALE; IMMUNIZATION; INTERFERON-GAMMA; LIFE CYCLE STAGES; LIVER; MALARIA; MEROZOITES; MICE; MICE, INBRED C57BL; PLASMODIUM BERGHEI; SPOROZOITES;

EID: 77955605526     PISSN: 19466234     EISSN: 19466242     Source Type: Journal    
DOI: 10.1126/scitranslmed.3001058     Document Type: Article

References (49)

1. World Health Organization, Malaria Report 2008 (World Health Organization, Geneva, 2008).
2. W. P. O'Meara, P. Bejon, T. W. Mwangi, E. A. Okiro, N. Peshu, R. W. Snow, C. R. Newton, K. Marsh, Effect of a fall in malaria transmission on morbidity and mortality in Kilifi, Kenya. Lancet 372, 1555-1562 (2008).
3. A. Bhattarai, A. S. Ali, S. P. Kachur, A. Mårtensson, A. K. Abbas, R. Khatib, A. W. Al-Mafazy, M. Ramsan, G. Rotllant, J. F. Gerstenmaier, F. Molteni, S. Abdulla, S. M. Montgomery, A. Kaneko, A. Björkman, Impact of artemisinin-based combination therapy and insecticide-treated nets on malaria burden in Zanzibar. PLoS Med. 4, e309 (2007).
4. B. M. Greenwood, Control to elimination: Implications for malaria research. Trends Parasitol. 24, 449-454 (2008).
5. S. L. Hoffman, D. L. Doolan, Malaria vaccines - targeting infected hepatocytes. Nat. Med. 6, 1218-1219 (2000).
6. M. F. Good, Vaccine-induced immunity to malaria parasites and the need for novel strategies. Trends Parasitol. 21, 29-34 (2005).
7. O. Silvie, M. M. Mota, K. Matuschewski, M. Prudêncio, Interactions of the malaria parasite and its mammalian host. Curr. Opin. Microbiol. 11, 352-359 (2008).
8. A. K. Mueller, M. Labaied, S. H. Kappe, K. Matuschewski, Genetically modified Plasmodium parasites as a protective experimental malaria vaccine. Nature 433, 164-167 (2005).
9. L. A. Purcell, S. K. Yanow, M. Lee, T. W. Spithill, A. Rodriguez, Chemical attenuation of Plasmodium berghei sporozoites induces sterile immunity in mice. Infect. Immun. 76, 1193-1199 (2008).
10. K. Matuschewski, Hitting malaria before it hurts: Attenuated Plasmodium liver stages. Cell. Mol. Life Sci. 64, 3007-3011 (2007).
11. W. R. Ballou, Obstacles to the development of a safe and effective attenuated pre-erythrocytic stage malaria vaccine. Microbes Infect. 9, 761-766 (2007).
12. S. L. Hoffman, L. M. Goh, T. C. Luke, I. Schneider, T. P. Le, D. L. Doolan, J. Sacci, P. de la Vega, M. Dowler, C. Paul, D. M. Gordon, J. A. Stoute, L. W. Church, M. Sedegah, D. G. Heppner, W. R. Ballou, T. L. Richie, Protection of humans against malaria by immunization with radiation-attenuated Plasmodium falciparum sporozoites. J. Infect. Dis. 185, 1155-1164 (2002).
13. M. Roestenberg, M. McCall, J. Hopman, J. Wiersma, A. J. Luty, G. J. van Gemert, M. van de Vegte-Bolmer, B. van Schaijk, K. Teelen, T. Arens, L. Spaarman, Q. de Mast, W. Roeffen, G. Snounou, L. Rénia, A. van der Ven, C. C. Hermsen, R. Sauerwein, Protection against a malaria challenge by sporozoite inoculation. N. Engl. J. Med. 361, 468-477 (2009).
14. M. Yu, T. R. Kumar, L. J. Nkrumah, A. Coppi, S. Retzlaff, C. D. Li, B. J. Kelly, P. A. Moura, V. Lakshmanan, J. S. Freundlich, J. C. Valderramos, C. Vilcheze, M. Siedner, J. H. Tsai, B. Falkard, A. B. Sidhu, L. A. Purcell, P. Gratraud, L. Kremer, A. P. Waters, G. Schiehser, D. P. Jacobus, C. J. Janse, A. Ager, W. R. Jacobs Jr., J. C. Sacchettini, V. Heussler, P. Sinnis, D. A. Fidock, The fatty acid biosynthesis enzyme FabI plays a key role in the development of liver-stage malarial parasites. Cell Host Microbe 4, 567-578 (2008).
15. A. B. Sidhu, Q. Sun, L. J. Nkrumah, M. W. Dunne, J. C. Sacchettini, D. A. Fidock, In vitro efficacy, resistance selection, and structural modeling studies implicate the malarial parasite apicoplast as the target of azithromycin. J. Biol. Chem. 282, 2494-2504 (2007).
16. C. D. Goodman, V. Su, G. I. McFadden, The effects of anti-bacterials on the malaria parasite Plasmodium falciparum. Mol. Biochem. Parasitol. 152, 181-191 (2007).
17. M. E. Fichera, D. S. Roos, A plastid organelle as a drug target in apicomplexan parasites. Nature 390, 407-409 (1997).
18. D. Burkhardt, J. Wiesner, N. Stoesser, M. Ramharter, A. C. Uhlemann, S. Issifou, H. Jomaa, S. Krishna, P. G. Kremsner, S. Borrmann, Delayed parasite elimination in human infections treated with clindamycin parallels 'delayed death' of Plasmodium falciparum in vitro. Int. J. Parasitol. 37, 777-785 (2007).
19. E. L. Dahl, P. J. Rosenthal, Multiple antibiotics exert delayed effects against the Plasmodium falciparum apicoplast. Antimicrob. Agents Chemother. 51, 3485-3490 (2007).
20. S. L. Andersen, A. L. Ager, P. McGreevy, B. G. Schuster, W. Ellis, J. Berman, Efficacy of azithromycin as a causal prophylactic agent against murine malaria. Antimicrob. Agents Chemother. 38, 1862-1863 (1994).
21. W. Peters, E. E. Davies, B. L. Robinson, The chemotherapy of rodent malaria. XXIII. Causal prophylaxis. Part II. Practical experience with Plasmodium yoelii nigeriensis in drug screening. Ann. Trop. Med. Parasitol. 69, 311-328 (1975).
22. B. Lell, P. G. Kremsner, Clindamycin as an antimalarial drug: Review of clinical trials. Antimicrob. Agents Chemother. 46, 2315-2320 (2002).
23. M. W. Dunne, N. Singh, M. Shukla, N. Valecha, P. C. Bhattacharyya, V. Dev, K. Patel, M. K. Mohapatra, J. Lakhani, R. Benner, C. Lele, K. Patki, A multicenter study of azithromycin, alone and in combination with chloroquine, for the treatment of acute uncomplicated Plasmodium falciparum malaria in India. J. Infect. Dis. 191, 1582-1588 (2005).
24. A. E. Girard, D. Girard, A. R. English, T. D. Gootz, C. R. Cimochowski, J. A. Faiella, S. L. Haskell, J. A. Retsema, Pharmacokinetic and in vivo studies with azithromycin (CP-62,993), a new macrolide with an extended half-life and excellent tissue distribution. Antimicrob. Agents Chemother. 31, 1948-1954 (1987).
25. A. K. Mueller, N. Camargo, K. Kaiser, C. Andorfer, U. Frevert, K. Matuschewski, S. H. Kappe, Plasmodium liver stage developmental arrest by depletion of a protein at the parasite-host interface. Proc. Natl. Acad. Sci. U.S.A. 102, 3022-3027 (2005).
26. E. D. Putrianti, O. Silvie, M. Kordes, S. Borrmann, K. Matuschewski, Vaccine-like immunity against malaria by repeated causal-prophylactic treatment of liver-stage Plasmodium parasites. J. Infect. Dis. 199, 899-903 (2009).
27. A. Sturm, R. Amino, C. van de Sand, T. Regen, S. Retzlaff, A. Rennenberg, A. Krueger, J. M. Pollok, R. Menard, V. T. Heussler, Manipulation of host hepatocytes by the malaria parasite for delivery into liver sinusoids. Science 313, 1287-1290 (2006).
28. J. Mazumdar, B. Striepen, Make it or take it: Fatty acid metabolism of apicomplexan parasites. Eukaryot. Cell 6, 1727-1735 (2007).
29. + T cells against Plasmodium liver stages: Immunobiology of an 'unnatural' immune response. Immunol. Rev. 225, 272-283 (2008).
30. K. A. Kumar, G. Sano, S. Boscardin, R. S. Nussenzweig, M. C. Nussenzweig, F. Zavala, V. Nussenzweig, The circumsporozoite protein is an immunodominant protective antigen in irradiated sporozoites. Nature 444, 937-940 (2006).
31. E. Belnoue, F. T. Costa, T. Frankenberg, A. M. Vigário, T. Voza, N. Leroy, M. M. Rodrigues, I. Landau, G. Snounou, L. Rénia, Protective T cell immunity against malaria liver stage after vaccination with live sporozoites under chloroquine treatment. J. Immunol. 172, 2487-2495 (2004).
32. C. Guerin-Marchand, P. Druilhe, B. Galey, A. Londono, J. Patarapotikul, R. L. Beaudoin, C. Dubeaux, A. Tartar, O. Mercereau-Puijalon, G. Langsley, A liver-stage-specific antigen of Plasmodium falciparum characterized by gene cloning. Nature 329, 164-167 (1987).
33. World Health Organization, Guidelines for the Treatment of Malaria (World Health Organization, Geneva, 2006).
34. R. A. Kuschner, D. G. Heppner, S. L. Andersen, B. T. Wellde, T. Hall, I. Schneider, W. R. Ballou, G. Foulds, J. C. Sadoff, B. Schuster, D. N. Taylor, Azithromycin prophylaxis against a chloroquine-resistant strain of Plasmodium falciparum. Lancet 343, 1396-1397 (1994).
35. I. Nebie, A. B. Tiono, D. A. Diallo, S. Samandoulougou, A. Diarra, A. T. Konate, N. Cuzin-Ouattara, M. Theisen, G. Corradin, S. Cousens, A. S. Ouattara, E. Ilboudo-Sanogo, B. S. Sirima, Do antibody responses to malaria vaccine candidates influenced by the level ofmalaria transmission protect from malaria? Trop. Med. Int. Health 13, 229-237 (2008).
36. R. M. DeHaan, C. M. Metzler, D. Schellenberg, W. D. VandenBosch, E. L. Masson, Pharmacokinetic studies of clindamycin hydrochloride in humans. Int. J. Clin. Pharmacol. 6, 105-119 (1972).
37. T. C. Porco, T. Gebre, B. Ayele, J. House, J. Keenan, Z. Zhou, K. C. Hong, N. Stoller, K. J. Ray, P. Emerson, B. D. Gaynor, T. M. Lietman, Effect of mass distribution of azithromycin for trachoma control on overall mortality in Ethiopian children: A randomized trial. JAMA 302, 962-968 (2009).
38. R. M. Chico, R. Pittrof, B. Greenwood, D. Chandramohan, Azithromycin-chloroquine and the intermittent preventive treatment of malaria in pregnancy. Malar. J. 7, 255 (2008).
39. T. N. Wells, P. L. Alonso, W. E. Gutteridge, New medicines to improve control and contribute to the eradication of malaria. Nat. Rev. Drug Discov. 8, 879-891 (2009).
40. C. S. Karunakaran, A clinical trial of malaria prophylaxis using a single dose of chloroquine at different intervals in an endemic malarious area. J. Trop. Med. Hyg. 83, 195-201 (1980).
41. D. J. Fryauff, J. K. Baird, Purnomo, M. Awalludin, T. Jones, B. Subianto, T. L. Richie, E. Tjitra, F. S. Wignall, S. L. Hoffman, Malaria in a nonimmune population after extended chloroquine or primaquine prophylaxis. Am. J. Trop. Med. Hyg. 56, 137-140 (1997).
42. A. M. Bradley-Moore, B. M. Greenwood, A. K. Bradley, A. Akintunde, E. D. Attai, A. F. Fleming, F. V. Flynn, B. R. Kirkwood, H. M. Gilles, Malaria chemoprophylaxis with chloroquine in young Nigerian children. IV. Its effect on haematological measurements. Ann. Trop. Med. Parasitol. 79, 585-595 (1985).
43. J. J. Aponte, C. Menendez, D. Schellenberg, E. Kahigwa, H. Mshinda, P. Vountasou, M. Tanner, P. L. Alonso, Age interactions in the development of naturally acquired immunity to Plasmodium falciparum and its clinical presentation. PLoS Med. 4, e242 (2007).
44. P. L. Alonso, J. Sacarlal, J. J. Aponte, A. Leach, E. Macete, P. Aide, B. Sigauque, J. Milman, I. Mandomando, Q. Bassat, C. Guinovart, M. Espasa, S. Corachan, M. Lievens, M. M. Navia, M. C. Dubois, C. Menendez, F. Dubovsky, J. Cohen, R. Thompson, W. R. Ballou, Duration of protection with RTS,S/AS02A malaria vaccine in prevention of Plasmodium falciparum disease in Mozambican children: Single-blind extended follow-up of a randomised controlled trial. Lancet 366, 2012-2018 (2005).
45. D. Kitamura, J. Roes, R. Kühn, K. Rajewsky, A B cell-deficient mouse by targeted disruption of the membrane exon of the immunoglobulin m chain gene. Nature 350, 423-426 (1991).
46. C. J. Janse, B. Franke-Fayard, G. R. Mair, J. Ramesar, C. Thiel, S. Engelmann, K. Matuschewski, G. J. van Gemert, R. W. Sauerwein, A. P. Waters, High efficiency transfection of Plasmodium berghei facilitates novel selection procedures. Mol. Biochem. Parasitol. 145, 60-70 (2006).
47. Abbreviations for the amino acids are as follows: A, Ala; D, Asp; E, Glu; F, Phe; I, Ile; K, Lys; M, Met; N, Asn; P, Pro; R, Arg; S, Ser; T, Thr; and V, Val.
48. A. K. Mueller, M. Deckert, K. Heiss, K. Goetz, K. Matuschewski, D. Schlüter, Genetically attenuated Plasmodium berghei liver stages persist and elicit sterile protection primarily via CD8 T cells. Am. J. Pathol. 171, 107-115 (2007).
49. Acknowledgments: We thank I. Arnold, M. Ganter, D. Scheppan, and C. Nahar for assistance and K. Marsh and E. Schieck for discussions and comments on the manuscript. Funding: This work was supported by the Deutsche Forschungsgemeinschaft (SFB 544, A7, and B10), the European Commission (BioMalPar, #23), Joachim Siebeneicher Foundation, the Chica and Heinz Schaller Foundation, and the KenyaMedical Research Institute-Wellcome Trust Research Programme, Kilifi. The funders had no role in study design; data collection; and analysis, decision to publish, or preparation of the manuscript. E.D.P. is a scholar of the Deutscher Akademischer Auslandsdienst. O.S. was a recipient of a Marie Curie Intra-European fellowship and is supported by a European Molecular Biology Organization long-term fellowship. J.C.R.H. is a University Research Fellow of The Royal Society (UK). Author contributions: J.F., E.D.P., O.S., and J.C.R.H. performed the experiments. J.F., O.S., J.C.R.H., K.M., and S.B. planned the experiments and analyzed the data. J.F., O.S., K.M., and S.B. wrote the manuscript. Competing interests: The authors declare that they have no competing interests.